Impact cone and plate(let) analyzer

Platelets, Second Edition

Volumn , Issue , 2006, Pages 535-544

  Varon, David ^a   Savion, Naphtali ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85148831074     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50791-6     Document Type: Chapter

References (38)

1. S. Einav, C.F. Dewey and H. Hartenbaum (1994) Cone and plate apparatus: A compact system for studying well characterized flow fields. Exper Fluids 16 196-202.
2. D. Varon, R. Dardik, S. Shenkman, et al. (1997) A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 85 283-294.
3. B. Shenkman, N. Savion, R. Dardik, et al. (1999) Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate (let) analyzer: Role of platelet activation, fibrinogen and Willebrand factor. Thromb Res 99 353-361.
4. E.I.B. Peerschke, R.T. Silver, B. Weksler, et al. (2004) Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: Effect of platelet antagonists. Br J Haematol 127 195-203.
5. N. Savion, B. Shenkman, I. Tamarin, et al. (2001) Transient adhesion refractoriness of circulating platelets under shear stress: The role of partial activation and microaggregate formation by suboptimal ADP c. Br J Hematol 112 1055-1061.
6. O. Gurevitz, A. Goldfarb, H. Hod, et al. (1998) Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. Arterioscler Thromb Vasc Biol 18 200-207.
7. A. Inbal, O. Gurevitz, I. Tamarin, et al. (1999) Unique antiplatelet effects of a novel S-nitroso derivative of a recombinant fragment of von Willebrand factor, AR545C: In vitro and ex vivo inhibition of pla function. Blood 94 1693-1700.
8. R. Dardik, D. Varon, R. Eskaraev, et al. (2000) Recombinant fragment of von Willebrand factor AR545C inhibits platelets binding to thrombin and platelet adhesion of thrombin-treated endothelial cells. Br J Haematol 109 512-518.
9. G. Kenet, A. Lubetsky, B. Shenkman, et al. (1998) Cone and platelet analyser (CPA): A new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 101 255-259.
10. R.W. Colman (1990) Platelet and neutrophil activation in cardiopulmonary bypass. Ann Thorac Surg 49 32-34.
11. A. Weerasinghe and K.M. Taylor (1998) The platelets in cardiopulmonary bypass. Ann Thorac Surg 66 2145-2152.
12. R. Gerrah, E. Snir, A. Brill, et al. (2004) Platelet function changes as monitored by cone and plate(let) analyzer during beating heart surgery. Heart Surg Forum 7 E191-E195.
13. A. Lubetsky, R. Jarrach, A. Brill, et al. (2002) Cone and plate(let) parameters as predictors of bleeding in patients undergoing cardiac surgery. Blood 100 2720.
14. D. Varon, I. Lashevski, B. Brenner, et al. (1998) Cone and plate(let) analyzer: Monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under conditions. Am Heart J 135 187-193.
15. B. Shenkman, J. Schneiderman, I. Tamarin, et al. (2001) Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: Correlation between standard aggregometry, flow cytometry and the cone an plate(let) analyzer (CPA) methods. Thromb Res 102 311-317.
16. J.I. Osende, V. Fuster, E.I. Lev, et al. (2001) Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests — Relevance for monitoring long-term glycoprotein I inhibition. Circulation 103 1488-1491.
17. X.K. Wang, R.T. Dorsam, A. Lauver, et al. (2002) Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion. J Pharmacol Exp Ther 303 1114-1120.
18. C.M. Helgason, K.M. Bolin, J.A. Hoff, et al. (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25 2331-2336.
19. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, et al. (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 961-965.
20. J.W. Eikelboom, J. Hirsh, J.I. Weitz, et al. (2002) Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular e. Circulation 105 1650-1655.
21. K.H. Grotemeyer, H.W. Scharafinski and I.W. Husstedt (1993) Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Thromb Res 71 397-403.
22. S.D. Wiviott and E.M. Antman (2004) Clopidogrel resistance: A new chapter in a fast-moving story. Circulation 109 3064-3067.
23. S. Matetzky, B. Shenkman, V. Guetta, et al. (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 3171-3175.
24. G. Spectre, A. Brill, A. Gural, et al. (2005) A new point-of-care method for monitoring anti-platelet therapy: Application of the Cone and Plate(let) Analyzer. Platelets 16 293-299.
25. B. Shenkman, S. Matetzky, H. Hod, et al. (2006) High rate of unresponsiveness to clopidogrel in patients with acute coronary syndrome (ACS) as determined by the Impact-R [cone and Plate(let) Analyzer]. J Thromb Haemost 3(Suppl. 1), 2145. (abstr).
26. R. Tsabari, Y. Schwammenthal, S. Matetzky, et al. (2005) Low rate of responsiveness to aspirin in acute brain ischemia: Association with stroke severity and clinical outcome. Stroke 35 474. (abstr).
27. A.L. Frelinger, M.D. Linden, M.I. Furman, et al. (2004) Patients with coronary artery disease have an increased incidence of aspirin resistance: Association of PFA-100 closure time with clinical findings. Blood 104 514a. (abstr)
28. N. Abdelrahman, A. Brill, N. Turetsky, et al. (2004) High rate of aspirin resistance among patients undergoing percutaneous interventions for unstable angina is associated with clinical outcome. Blood 104 515a. (abstr).
29. M. Furlan (1996) Willebrand factor: Molecular size and functional activity. Ann Hematol 72 341-348.
30. P.M. Manucci, M.T. Canciani, I. Forza, et al. (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98 2730-2735.
31. J.F. Dong, J. Whitelock, A. Bernardo, et al. (2004) Variations among normal individuals in the cleavage of endothelialderived ultra-large von Willebrand factor under flow. J Thromb Haemost 2 1460-1466.
32. G.G. Levy, W.C. Nichols, E.C. Lian, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 488-494.
33. H.M. Tsai and E.C. Lian (1998) Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 1585-1589.
34. Y. Frishberg, T.G. Obrig, B.S. Kaplan (1994) Hemolytic uremic syndrome. M.A. Hollyday, et al., (Ed.) Pediatric nephrology 3rd ed Baltimore, MD: Williams and Wilkins 871-889.
35. B.J. Hunt, B. Lammle, C.H.F. Nevard, et al. (2001) Von Willebrand factor-cleaving protease in childhood diarrheaassociated haemolytic uraemic syndrome. Thromb Haemost 85 975-978.
36. B. Shenkman, A. Inbal, I. Tamarin, et al. (2003) Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition. Br J Haematol 120 597-604.
37. B. Shenkman, U. Budde, D. Angerhaus, et al. (2006) ADAMTS-13 effect on platelet adhesion under flow: A new method for differentiation between inherited and acquired thrombotic thrombocytopenic purpura. Thromb Haemost in press.
38. S. Gitel, A. Brill, N. Savion, et al. (2006) Platelet mediated clot formation in whole blood under flow: A new screening method for coagulation disorders and for drug monitoring. J Thromb Haemost 3(Suppl. 1), 2169. (abstr).